Lucie Karayan (225x250)

EQUIPE de rattachement : Equipe 1 : Pr Afsaneh Gaillard

NOM Prénom : Karayan-Tapon Lucie

Statut (date de début-fin prévue si CDD):

University Professor and Hospital Practitioner (PU-PH). Head of Cancer Biology depatment at the CHU de Poitiers and Head of Poitiers Cancer Molecular Genetics Platform

Adresse :  Laboratoire de Cancérologie Biologique, UBM 1er étage , Rue de la milétrie, CHU de Poitiers

Tél : 0549444988

e-mail : l.karayan-tapon@chu-poitiers.fr

Publications (toutes les marquantes, y compris avant 2012)

  1. Balbous A,  Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.  BMC Cancer (2016) 5;16:604.
  2. Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.Oncotarget. (2016) Aug 17.
  3. Tougeron D, Guilloteau K, Karayan-Tapon L. Absence of IDH mutation in colorectal cancers with microsatellite instability. Dig Liver Dis. (2016) 48(6):681-3
  4. Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. J Natl Cancer Inst. (2016) Feb 1;108(7).
  5. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributorsRoutine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. (2016) 2;387(10026):1415-26.
  6. Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, Arnaud P. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients’ survival. Carcinogenesis. (2016) 37(2):169-76.
  7. Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Lecomte T; Association des Gastro-Entérologues Oncologues (AGEO).Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study. Eur J Cancer. (2015) 51(8):925-34.
  8. Cortes U, Guilloteau K, Rouvreau M, Archaimbault C, Villalva C, Karayan-Tapon L. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples. Exp Mol Pathol. (2015) 99(2):207-11.
  9. Akil H, Abbaci A, Lalloué F, Bessette B, Costes LM, Domballe L, Charreau S, Guilloteau K, Karayan-Tapon L, Bernard FX, Morel F, Jauberteau MO, Lecron JC. IL22/IL-22R pathway induces cell survival in human glioblastoma cells. PLoS One. (2015) 20;10(3):e0119872
  10. Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L (2014). Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma. Mol Cancer Ther 13(9):2159-69.
  11. Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, Taillandier L. (2014) Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas. Eur J Cancer. 50(13):2364-6.
  12. Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, Chomel JC, Karayan-Tapon L (2014). A mesenchymal glioma stem cell profile is related to clinical outcome.Oncogenesis. 17;3:
  13. Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J. (2014). DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.PLoS One. 18;9(9):e104455.
  14. Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L, Mosser J, Ichimura K, Figarella-Branger D. (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol. 116(3):487-96.
  15. Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P; BRAF EQA Group (2013) Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer. 11;13:472. 1471-2407
  16. Villalva, C., Duranton-Tanneur, V., Guilloteau, K., Burel-Vandenbos, F., Wager, M., Doyen, J., Levillain, P., Fontaine, D., Blons. H., Pedeutour. F., Karayan-Tapon, L. (2013). EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med;2 :296-304.
  17. Tougeron, D., Cortes, U., Ferru, A., Villalva, C., Silvain, C., Tourani, J.M., Levillain, P., Karayan-Tapon L. (2013). Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol;72 :397-403.
  18. Tougeron, D., Lecomte, T., Pagès, J.C., Villalva, C., Collin, C., Ferru, A., Tourani, J.M., Silvain, C., Levillain, P., Karayan-Tapon L. (2013). Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol ;24 :1267-1273.
  19. Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L. (2012) O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions. Int J Mol Sci. 13(6):6983-94.
  20. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D. (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 1;118(17):4201-11
  21. Villalva C., Martin-Lannerée S.Cortes U., Dkhissi F., Wager M., LeCorf A., Tourani JM.,  Dusanter-Fourt I., Turhan AG and Karayan-Tapon L.  (2011) STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy ? International Journal of Cancer 128(4): 826-38
  22. Dominguez C., Karayan-Tapon L., Desurmont T., Gibelin H., Crespin S., Fromont G., Levillain P., Bouche G., Cantereau A., Mesnil M., Kraimps JL.  (2011) Altered Expression of the Gap Junction Protein, Connexin43, Is Associated with Papillary Thyroid Carcinomas When Compared with Other Noncancer Pathologies of the Thyroid. Thyroid 21 : 1057-66.
  23. Cheray M, Petit D, Forestier L, Karayan-Tapon L, Maftah A, Jauberteau MO, Battu S, Gallet FP, Lalloué F (2011). Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells. Cancer Lett. 15;312(1):24-32.
  24. Working Group of the Institut National du Cancer. (2011) Guidelines for hospital molecular genetics platforms of cancers. Institut National du Cancer]. Ann Pathol. 31(3):135-7
  25. Karayan-Tapon L., Quillien V., Guilhot J., Wager M., Fromont G., Saikali S., Etcheverry A., Hamlat A., Loussouarn D., Campion L., Campone M., Vallette FM., Gratas-Rabbia-Ré C. (2010) Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncology. 97:311-22
  26. Ducray F., de Reyniès A., Chinot O., Idbaih A., Figarella-Branger D., Colin C., Karayan-Tapon L., Chneiweiss H., Wager M., Vallette F., Marie Y., Rickman D., Thomas E., Delattre JY., Honnorat J., Sanson M., Berger F. (2010) An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients Molecular Cancer. 9: 234
  27. Fontaine JF., Mirebeau-Prunier D., Raharijaona M., Franc B., Triau S., Rodien P., Goëau-Brissonniére O., Karayan-Tapon L., Mello M., Houlgatte R., Malthiery Y., Savagner F. (2009) Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.  PLoS One. 4(10):e7632.
  28. Wager M., Menei P., Guilhot J., Levillain P., Michalak S., Bataille B., Blanc JL., Lapierre F., Rigoard P., Milin S., Duthe F., Bonneau D., Larsen CJ and Karayan-Tapon L. (2008) Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. British Journal of Cancer, 98(11):1830-8.
  29. Karayan-Tapon L., Wager  M., Guilhot   J., Levillain P., Marquant C., Clarhaut J., Potiron V. and  Roche J. (2008)  Semaphorin, Neuropilin and VEGF expression in glial tumors : SEMA3G, a prognostic marker ? British Journal of Cancer, 99(7):1153-60. 21.
  30. Ferru A., Denis S., Guilhot J., Gibelin H., Tourani J.M, Kraimps J.L, Larsen CJ and Karayan-Tapon L. (2006). Expression of TAp73, DTAp73 isoform transcripts in thyroid tumors. European Journal of Surgical Oncology,32: 228-230
  31. Wager M., Guilhot J., Blanc JL., Ferrand S., Bataille B., Lapierre F., Denis S., Chantereau T., Larsen CJ and Karayan-Tapon L. (2006) Prognostic value of increase in transcript levels of Tp73 DEx2-3 isoforms in low-grade glioma patients British Journal of Cancer, 95: 1062-1069
  32. Ferru A., Fromont G, Gibelin H, Guilhot J., Savagner F., Tourani J.M, Kraimps J.L, Larsen CJ and Karayan-Tapon L. (2006) The status of CDKN2A alpha (p16INK4a) and beta (p14ARF) transcripts in thyroid tumor progression. British Journal of Cancer, 21: 1-8
  33. Karayan-Tapon L., Menet E., Guilhot J., Levillain P., Larsen C.J. and Kraimps J.L. (2004). Topoisomerase II alpha expression is not related to Telomerase activity in Papillary Thyroid Carcinomas. European Journal of Surgical Oncology, 30 :73-79.
  34. Blanc JL., Wager M, Guilhot J., Cusy S., Bataille B., Chantereau T., Lapierre F., Larsen C.J. and Karayan-Tapon L. (2004). Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. Journal of Neuro-Oncology, 68: 275-283
  35. Ayrault O., Karayan L., Larsen C.J. and Seité P. (2003). Delineation of domains of protein  p14ARF involved in physical and functional interaction with Topoisomerse I. Oncogene , 2 (13) : 1945-1954.
  36. Karayan L., Riou J.F, Séité P., Migeon J., Cantereau A., and Larsen C.J. (2001). Human ARF protein interacts with Topoisomerase I and stimulates its activity. Oncogene, 20, (7): 836-848
  37. Eymin B., Karayan L., Séité P., Brambilla C., Brambilla E., Larsen C.J. and Gazzéri S. (2001). Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene, 20, (9): 1033-1041
  38. Karayan L.*, Hong S.S.*, Gay B.*, Dabauvalle M.C., Boulanger P.A. (1999). Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology, 15:262(1): 163-177 (* contribution égale)
  39. Karayan L., Hong S.S., Gay B., Tournier J., Dupuy d’Angeac A. and Boulanger P.A. (1997). Stuctural and Functional Determinants in Adenovirus Type 2 Penton Base Recombinant Protein. Journal of Virology, 71: 8678-8689
  40. Hong S.S., Karayan L., Tournier J., Curiel D. T. and Boulanger P. A. (1997). Adenovirus type 5 fiber knob binds to MHC classe I a2 domain at the surface of human epithelial and B lymphoblastoid cells. The EMBO Journal, 16: 2294-2306


Menu principal

Haut de page